MedTrace Logo

Upfront Combination Pulmonary Arterial Hypertension Therapy

NCT03809156 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-03-26

No results posted yet for this study

Summary

To evaluate the safety and efficacy of first-line combination therapy using riociguat with ambrisentan in patients with Pulmonary Arterial Hypertension (PAH).

Conditions

  • Pulmonary Hypertension

Interventions

DRUG

Riociguat Oral Product

Dual therapy of Riociguat and Ambrisentan at initiation of treatment.

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • University of Calgary

    lead OTHER

Principal Investigators

  • Naushad Hirani, MD · University of Calgary

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-26
Primary Completion
2020-12-31
Completion
2021-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03809156 on ClinicalTrials.gov